LAGUNA NIGUEL, CA -- (Marketwire) -- 10/07/12 -- The Biotech Meeting, an annual gathering of life sciences CEOs now in its 25th year, tonight announced the 2012 inductees to The Biotechnology Hall of Fame during its annual awards dinner. The conference is hosted annually for the CEOs by Burrill & Company and Kleiner Perkins Caufield & Byers.
Industry CEOs and attendees of the meeting selected the inductees. The selections represent the leaders of the industry acknowledging the accomplishments of their most admired and respected peers.
"During the 25 years that we have held this meeting we have seen this industry prosper and grow beyond most people's imaginations," says G. Steven Burrill, CEO of Burrill & Company, a global financial services firm focused exclusively on the life sciences. "We have seen visionary CEOs, entrepreneurs, and researchers triumph over business, financial, and scientific challenges to forge a new industry. We are pleased to welcome these inductees into our Hall of Fame and honor them for their contributions in building our industry."
The following companies have been inducted to the Hall of Fame in the category of Leading Companies:
The following people have been inducted into the Hall of Fame in the category of Outstanding Individuals:
The following people, companies, products, and discoveries have been inducted into the Hall of Fame in the category of Scientific Achievement:
"We are living in an historic time today as biotechnology addresses mankind's greatest challenges to not only improve healthcare, but to feed and fuel a growing world," says Brook Byers, partner with Kleiner Perkins Caufield & Byers. "Tonight, we salute a group of risk-taking individuals with a rare combination of vision, creativity, and intelligence. We look forward to honoring those who will follow in their footsteps and to seeing where they will take us in the next 25 years."
Previous Hall of Fame Inductees:
Human Genome Sciences
IDEC Pharmaceuticals Corporation
G. Steven Burrill (special Millennium award)
Brook Byers (special Millennium award)
Marc Feldmann and Ravinder N. Maini for the discovery of anti-TNF therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases
Jan Vilcek for anti-TNF MAb Remicade, alpha-interferon, beta interferon for MS
Eric Lander for his pioneering work in sequencing and PCAST
Genentech for Herceptin/HER2
Harold Varmus and Mike Bishop for oncogenes
Francis Collins for the Human Genome Project
Napoleone Ferrara for Human VEGF
Andrew Fire and Craig Mello for RNA Interference
Robert Langer for drug delivery
Doug Melton and Tom Jessell for stem cells
Brian J. Druker for Gleevec
Judah Folkman for his work on the first purified angiogenesis molecule, the first angiogenesis inhibitor, the concept on angiogenic disease, and the resulting clinical trials based on his work
Darrell Anderson, Nabil Hanna, William Rastetter, and Antonio Grillo-Lopez for their discovery and development of the antibody Rituxan marketed by Idec, Genentech, and Roche
Affymetrix for its gene array technology
Agouron for its structure based design of Viracept HIV protease inhibitor
Chiron for its work in HCV and DNA
Medarex and Abgenix for development of human monoclonal antibodies
Protein Design Labs for humanizing of monoclonal antibodies
James Thomson for his discovery of stem cells
Celera for deciphering of the human genome
Roslin Institute for the production of Dolly, the sheep clone, using nuclear transfer
Amgen for cloning of EPO and the discovery and development of Neupogen
Stanley Cohen and Herb Boyer for recombinant DNA
Leroy Hood for automated sequencing of DNA
Caesar Millstein for monoclonal antibodies
Cetus Corporation for PCR
Genentech for Humilin and TPA
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.
About Kleiner Perkins Caufield & Byers
Since its founding in 1972, Kleiner Perkins Caufield & Byers has backed entrepreneurs in more than 500 ventures including AOL, Amazon.com, Citrix, Compaq, Electronic Arts, Genentech, Gen-Probe, Genomic Health, Google, Idec Pharmaceuticals, Intuit, Juniper Networks, Netscape, Sun, Symantec, Verisign, webMD and Zynga. KPCB portfolio companies employ more than 400,000 people worldwide. More than 200 of the firm's portfolio companies have gone public, and many other KPCB ventures have achieved success through mergers and acquisitions. KPCB focuses its global investments in three practice areas -- digital, greentech and life sciences -- and provides entrepreneurs with company-building expertise out of its offices in Silicon Valley, Beijing and Shanghai.